跳至主要内容
临床试验/JPRN-UMIN000045181
JPRN-UMIN000045181尚未招募未知

The Preferred Premedication Order to Prevent Infusion Reactions in Patients with Breast Cancer Receiving Pertuzumab plus Trastuzumab and Docetaxel - Prophylaxis for Infusion Reactions in Pertuzumab plus Trastuzumab and Docetaxel

Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital0 个研究点目标入组 100 人开始时间: 2021年8月18日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1) Serious drug hypersensitivity 2) Pregnant or lactation women, or women with suspected pregnancy 3) Other any cancer 4) Other severe complications AMI, heart failure, purmonary fibrosis, uncontrolled DM, severe infection and so on 5) Severe mental disorders 6) Active bleeding of digestive tract 7) Serious myeloablation, renal insufficciency, liver failure 8) Diarrhea 9) Active infection 10) Prior treatment with anti-HER2 therapy for breast cancer 11) Metastatic breast cancer 12) Under treatment with continuous systemic steroid, anti-allergic agent, anti-histamine agent, immunosuppresant, and NSAID 13) Not suitable for participating in the study for any other reason

研究者

发起方
Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital

相似试验